+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010624
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer immunotherapy drugs market is undergoing rapid transformation, driven by technological breakthroughs, strategic collaborations, and evolving clinical protocols. Senior leaders within life sciences, biopharma, and healthcare sectors must navigate this dynamic landscape, capitalizing on therapeutic innovation, regulatory shifts, and global expansion opportunities.

Market Snapshot: Cancer Immunotherapy Drugs Market Growth and Outlook

The Cancer Immunotherapy Drugs Market grew from USD 243.31 billion in 2024 to USD 276.52 billion in 2025. It is expected to continue growing at a CAGR of 13.15%, reaching USD 510.62 billion by 2030. This surge reflects a shift toward immune-based therapies as essential pillars in modern oncology, fueled by increasing clinical adoption, supportive regulatory pathways, and robust investment across regions.

Scope & Segmentation

This report delivers in-depth intelligence on emerging treatment modalities, evolving regional trends, and the operational, clinical, and commercial segments shaping the global cancer immunotherapy drugs market.

  • Mechanism Of Action: Cancer vaccines, chimeric antigen receptor (CAR) T cell therapies, CTLA-4 inhibitors, cytokines, oncolytic viruses, PD-1 inhibitors, and PD-L1 inhibitors. Each technology addresses unique tumor pathways, offering differentiated development routes and manufacturing implications.
  • Cancer Types: Indications include bladder cancer, kidney cancer, melanoma, lung cancer (with specific focus on non-small cell and small cell types), and hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. These segments reflect distinct immune response profiles and competitive pressures.
  • Treatment Line: First, second, and third line or beyond, capturing the evolving role of immunotherapies along patient care pathways.
  • Route Of Administration: Intravenous, oral, and subcutaneous. Each affects patient convenience, clinical logistics, and pharmacokinetic targeting.
  • End User: Hospitals, ambulatory care centers, and specialty clinics, each requiring tailored supply chain and administration solutions.
  • Distribution Channel: Hospital, retail, and online pharmacies, supporting diverse patient access strategies and fulfillment needs.
  • Geographic Regions: Americas (with key states such as California, Texas, New York, Florida, Illinois, Pennsylvania, and Ohio), Canada, Mexico, Brazil, Argentina, Europe, Middle East & Africa (including UK, France, Germany, Italy, Spain, Russia, UAE, Saudi Arabia, South Africa, and others), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan). These cover varying market entry challenges, reimbursement models, and innovation ecosystems.
  • Company Coverage: Strategic profiles and pipeline analyses of Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Johnson & Johnson, Gilead Sciences, Amgen Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Celldex Therapeutics, Inc.

Key Takeaways: Strategic Insights for Oncology Decision-Makers

  • Checkpoint inhibitors and cell-based immunotherapies continue to expand their reach, driven by advances in biomarker research, gene editing, and precision medicine platforms.
  • Regulatory agility in the Americas and Asia-Pacific accelerates time-to-market for novel immunotherapies, while fragmented reimbursement in EMEA encourages localized evidence and real-world data strategies.
  • Personalized regimens, supported by integrated biomarker panels and AI-driven models, lead to enhanced patient stratification and better response rates across cancer types.
  • Collaborations between academic research, biotechs, and pharmaceutical companies are essential for pipeline innovation, co-development, and overcoming manufacturing and access challenges.
  • Patient education and support initiatives are increasingly important for improving therapy adherence and addressing barriers in emerging markets and complex care environments.

Tariff Impact: 2025 United States Policy Changes

New United States tariffs set for implementation in 2025 are expected to impact biologics supply chains, raw material costs, and procurement strategies. Manufacturers may pivot to domestic sourcing or vertically integrate critical production components, and invest in continuous manufacturing to navigate tariff-related price pressures. These dynamics will require coordinated action across operations, payers, and regulatory teams to sustain competitive edge in the cancer immunotherapy sector.

Methodology & Data Sources

Findings are founded on rigorous primary research with industry experts and clinicians, supported by systematic secondary review of peer-reviewed publications, regulatory filings, and regional healthcare reports. Comprehensive data triangulation and cross-verification ensure market reliability and relevance.

Why This Report Matters

  • Supports executive strategic planning through detailed analysis of market dynamics, regulatory trends, and technology adoption in cancer immunotherapy drugs.
  • Enables targeted investment by clarifying pipeline opportunities, regional market variations, and operational risks associated with emerging tariff and policy changes.
  • Equips decision-makers with actionable intelligence on segmentation-driven opportunities, enabling more accurate forecasting and resource allocation.

Conclusion

This research equips leaders with actionable market insight and structured guidance for navigating cancer immunotherapy. Adaptable approaches and informed decision-making will be pivotal in shaping future oncology success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in dual-target CAR T cell engineering for solid tumor indications
5.2. Emergence of bispecific antibody therapies targeting PD-L1 and CTLA-4 checkpoints
5.3. Integration of mRNA vaccine platforms into personalized cancer immunotherapy pipelines
5.4. Adoption of AI driven biomarker discovery to predict patient immunotherapy response
5.5. Optimization of combination regimens integrating oncolytic viruses with checkpoint inhibitors
5.6. Development of neoantigen based personalized cancer vaccines using high throughput sequencing
5.7. Regulatory framework evolution impacting accelerated approval of novel immuno oncology agents
5.8. Expansion of intratumoral delivery technologies to enhance local immune activation in tumors
5.9. Real world evidence generation to assess long term safety and efficacy of CAR T therapies
5.10. Biomanufacturing scale up strategies to reduce cost of goods for autologous cell therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Immunotherapy Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR T Cell Therapies
8.4. CTLA-4 Inhibitors
8.5. Cytokines
8.6. Oncolytic Viruses
8.7. PD-1 Inhibitors
8.8. PD-L1 Inhibitors
9. Cancer Immunotherapy Drugs Market, by Cancer Type
9.1. Introduction
9.2. Bladder Cancer
9.3. Hematologic Malignancies
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Multiple Myeloma
9.4. Kidney Cancer
9.5. Lung Cancer
9.5.1. Non-Small Cell Lung Cancer
9.5.2. Small Cell Lung Cancer
9.6. Melanoma
10. Cancer Immunotherapy Drugs Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Cancer Immunotherapy Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Cancer Immunotherapy Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Cancer Immunotherapy Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Cancer Immunotherapy Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cancer Immunotherapy Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. AstraZeneca PLC
17.3.4. Johnson & Johnson
17.3.5. Gilead Sciences, Inc.
17.3.6. Amgen Inc.
17.3.7. Pfizer Inc.
17.3.8. Takeda Pharmaceutical Company Limited
17.3.9. Astellas Pharma Inc.
17.3.10. Celldex Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CANCER IMMUNOTHERAPY DRUGS MARKET: RESEARCHAI
FIGURE 28. CANCER IMMUNOTHERAPY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. CANCER IMMUNOTHERAPY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. CANCER IMMUNOTHERAPY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 120. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 121. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 124. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 125. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 126. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 127. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 128. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 129. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 140. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 141. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 142. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 222. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 223. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 224. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 225. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 226. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 227. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 238. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 239. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 240. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 241. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 242. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 266. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 267. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 268. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 269. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 270. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 271. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 272. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 273. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 274. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 275. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 284. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 285. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 286. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 287. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 288. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 289. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 290. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 291. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Immunotherapy Drugs market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Celldex Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 276.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 510.62 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030 - Product Image

Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Cancer Immunotherapy Market by Therapy Type (Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors), Mechanism Of Action (Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy), Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2025-2030 - Product Image

Cancer Immunotherapy Market by Therapy Type (Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors), Mechanism Of Action (Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy), Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030 - Product Image

Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030

  • Report
  • 110 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Oncology Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Oncology Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Drug Pipelines
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.